New limits on nucleon decays into invisible channels with the BOREXINO Counting Test Facility

The results of background measurements with the second version of the BOREXINO Counting Test Facility (CTF-II), installed in the Gran Sasso Underground Laboratory, were used to obtain limits on the instability of nucleons, bounded in nuclei, for decays into invisible channels ($inv$): disappearance, decays to neutrinos, etc. The approach consisted of a search for decays of unstable nuclides resulting from $N$ and $NN$ decays of parents $^{12}$C, $^{13}$C and $^{16}$O nuclei in the liquid scintillator and the water shield of the CTF. Due to the extremely low background and the large mass (4.2 ton) of the CTF detector, the most stringent (or competitive) up-to-date experimental bounds have been established: $\tau(n \to inv) > 1.8 \cdot 10^{25}$ y, $\tau(p \to inv) > 1.1 \cdot 10^{26}$ y, $\tau(nn \to inv) > 4.9 \cdot 10^{25}$ y and $\tau(pp \to inv) > 5.0 \cdot 10^{25}$ y, all at 90% C.L.Comment: 22 pages, 3 figures,submitted to Phys.Lett.

Genetic differentiation of Artemia franciscana (Kellogg, 1906) in Kenyan coastal saltworks

The nature of genetic divergence between the Artemia population native to San Francisco Bay, (SFB) USA and those from the introductions of SFB material in the Kenyan coast two decades ago were investigated using the mitochondrial DNA (mtDNA) and heat shock protein 70 (Hsp70) gene molecular markers. The DNA was extracted from 80 single Artemia cysts using the Chelex protocol. The 1,500 bp fragment of the 12S - 16S region of the mtDNA and a 1,935 bp fragment of the Hsp70 gene were amplified through Polymerase Chain Reaction (PCR) followed by Restriction Fragment Length Polymorphism (RFLP) digestion using appropriate endonucleases. The mtDNA analysis indicated higher haplotype diversity (0.76 ± 0.07) in Artemia from Fundisha saltworks while the rest of the samples were monomorphic. A private haplotype (AAABBA) in Fundisha samples confirmed a molecular evidence of a systematic genetic differentiation albeit in an insignificant manner (P > 0.05). There was molecular evidence of coexistence of SFB and GSL Artemia strains in Fundisha saltworks. The monomorphic DNA fingerprint in Kensalt Artemia cysts was probably caused by non-sequential Artemia culture system and limited mtDNA fragment size analysed. The Hsp70 gene RFLP fingerprint did not show any unique gene signatures in the Kenyan Artemia samples suggesting that other factors other than Hsp70 were involved in their superior thermotolerance. Further genetical studies based on the larger mtDNA fragment using robust genetic markers are recommended. Ecological studies of the heat shock protein family and the stress response would be more relevant than the qualitative RFLP technique

In vitro and in vivo anticryptococcal activities of a new pyrazolo-isothiazole derivative

We investigated the activity of a pyrazolo-isothiazole derivative (G8) against Cryptococcus neoformans. A first screening test showed that G8 at 10 mg/L inhibited the growth of 14 of 15 clinical isolated tested. Killing experiments showed that fungicidal activity was achieved after 8 h of treatment with G8 at concentration ≥ 10 mg/L. In a murine model of systemic cryptococcosis, G8 was effective at prolonging survival compared with the controls. Our data indicate that this new derivative has a potential therapeutic role in infections caused by C.neoformans

Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans

A checkerboard methodology, based on standardized methods proposed by the National Committee for Clinical Laboratory Standards for broth microdilution antifungal susceptibility testing, was applied to study the in vitro interactions of flucytosine (FC) and posaconazole (SCH 56592) (FC-SCH) against 15 isolates of Cryptococcus neoformans. Synergy, defined as a fractional inhibitory concentration (FIC) index of <0.50, was observed for 33% of the isolates tested. When synergy was not achieved, there was still a decrease in the MIC of one or both drugs when they were used in combination. Antagonism, defined as a FIC of >4.0, was not observed. The in vitro efficacy of combined therapy was confirmed by quantitative determination of the CFU of C. neoformans 486, an isolate against which the FC-SCH association yielded a synergistic interaction. To investigate the potential beneficial effects of this combination therapy in vivo, we established two experimental murine models of cryptococcosis by intracranial or intravenous injection of cells of C. neoformans 486. At 1 day postinfection, the mice were randomized into different treatment groups. One group each received each drug alone, and one group received the drugs in combination. While combination therapy was not found to be significantly more effective than each single drug in terms of survival, tissue burden experiments confirmed the potentiation of antifungal activity with the combination. Our study demonstrates that SCH and FC combined are significantly more active than either drug alone against C. neoformans in vitro as well in vivo. These findings suggest that this therapeutic approach could be useful in the treatment of cryptococcal infections

Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother.

A checkerboard methodology, based on standardized methods proposed by the National Committee for Clinical Laboratory Standards for broth microdilution antifungal susceptibility testing, was applied to study the in vitro interactions of flucytosine (FC) and posaconazole (SCH 56592) (FC-SCH) against 15 isolates of Cryptococcus neoformans. Synergy, defined as a fractional inhibitory concentration (FIC) index of 4.0, was not observed. The in vitro efficacy of combined therapy was confirmed by quantitative determination of the CFU of C. neoformans 486, an isolate against which the FC-SCH association yielded a synergistic interaction. To investigate the potential beneficial effects of this combination therapy in vivo, we established two experimental murine models of cryptococcosis by intracranial or intravenous injection of cells of C. neoformans 486. At 1 day postinfection, the mice were randomized into different treatment groups. One group each received each drug alone, and one group received the drugs in combination. While combination therapy was not found to be significantly more effective than each single drug in terms of survival, tissue burden experiments confirmed the potentiation of antifungal activity with the combination. Our study demonstrates that SCH and FC combined are significantly more active than either drug alone against C. neoformans in vitro as well in vivo. These findings suggest that this therapeutic approach could be useful in the treatment of cryptococcal infections

New experimental limits on heavy neutrino mixing in 8B- decay obtained with the BOREXINO counting test facility

If heavy neutrinos with mass mH 2me are emitted in the decays of 8B in the Sun, then H L + e+ + e- decays should be observed. In the present work, the results of background measurements with the Borexino Counting Test Facility have been used to obtain bounds on the number of these decays. As a result, new limits on the coupling |UeH|2 of a massive neutrino in the range of 1.1 MeV to 12 MeV have been derived (|UeH|2 10-3-10-5). The obtained limits on the mixing parameter are stronger than obtained in previous experiments using nuclear reactors and accelerators

Current Status of the BOREXINO experiment

The status of the BOREXINO experiment is presented. The physics potential of the experiment is reviewed